| 2024 | Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2024 | Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma | BIOORGANIC CHEMISTRY |
| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2023 | Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | CANCER |
| 2023 | A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
| CANCER RESEARCH AND TREATMENT |
| 2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination | JOURNAL OF GASTRIC CANCER |
| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2022 | Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A | ESMO OPEN |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2022 | Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2022 | Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study | CLINICAL CANCER RESEARCH |
| 2022 | Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
| EUROPEAN JOURNAL OF CANCER |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2022 | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
| NEURO-ONCOLOGY |
| 2022 | Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
| CANCERS |
| 2022 | Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01) | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2022 | First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2022 | Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma
| ESMO OPEN |
| 2021 | The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
| NATURE |
| 2021 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study | LANCET ONCOLOGY |
| 2021 | Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors | CLINICAL CANCER RESEARCH |
| 2021 | Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer | CELLULAR ONCOLOGY |
| 2021 | Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer
| CANCER MEDICINE |
| 2021 | Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
| GASTRIC CANCER |
| 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2021 | Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | TARGETED ONCOLOGY |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2021 | Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population
| GUT |
http://orcid.org/0000-0002-0920-9471
(7404006815)
